Hepatitis associated with prothionamide for treatment of multidrug-resistant tuberculosis

Han Lin Hsu, Kuan Jen Bai, Yi Chun Chiang, Shian Jiun Lin, Ming Chih Yu

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Timely and intensive monitoring for, and management of, adverse effects caused by anti-tuberculosis drugs are essential components of control programs for multidrug-resistant tuberculosis (MDR-TB). This retrospective case series was conducted in northern Taiwan from January 2007 to December 2008 at Taipei Medical University-Wan Fang Hospital, a 750-bed tertiary-care center and MDR-TB referral center. Hepatitis associated with prothionamide was defined as the recurrence of hepatitis after a second prothionamide treatment re-challenge. In total, 47 patients with MDR-TB enrolled in the Directly Observed Therapy, Short Course-Plus Program were identified during the study period, and 44 (93.6%) were treated with prothionamide. Seven of these 44 patients (15.9%) developed hepatitis after being treated with prothionamide concurrent with other anti-tuberculosis agents. Hepatitis associated with prothionamide occurred in three of these seven patients (6.8%). In these three patients, hepatitis developed following treatment with prothionamide for 28 days, 39 days or 45 days. Hepatitis developed rapidly after re-challenge with prothionamide at 4 days, 4 days and 3 days, respectively. Liver function returned to the normal range after cessation of prothionamide treatment for 19 days, 27 days or 28 days. Close monitoring of liver function was necessary in MDR-TB patients who received prothionamide treatment.

Original languageEnglish
Pages (from-to)923-927
Number of pages5
JournalJournal of the Formosan Medical Association = Taiwan yi zhi
Volume109
Issue number12
DOIs
Publication statusPublished - Dec 2010

Fingerprint

Prothionamide
Multidrug-Resistant Tuberculosis
Hepatitis
Therapeutics
Tuberculosis
Directly Observed Therapy
Essential Drugs
Withholding Treatment
Liver
Taiwan
Tertiary Care Centers
Reference Values
Referral and Consultation

Keywords

  • Hepatitis
  • Multidrug-resistant tuberculosis
  • Prothionamide

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hepatitis associated with prothionamide for treatment of multidrug-resistant tuberculosis. / Hsu, Han Lin; Bai, Kuan Jen; Chiang, Yi Chun; Lin, Shian Jiun; Yu, Ming Chih.

In: Journal of the Formosan Medical Association = Taiwan yi zhi, Vol. 109, No. 12, 12.2010, p. 923-927.

Research output: Contribution to journalArticle

@article{91b2e2d57f4c4b1ea2b17438a9d6a948,
title = "Hepatitis associated with prothionamide for treatment of multidrug-resistant tuberculosis",
abstract = "Timely and intensive monitoring for, and management of, adverse effects caused by anti-tuberculosis drugs are essential components of control programs for multidrug-resistant tuberculosis (MDR-TB). This retrospective case series was conducted in northern Taiwan from January 2007 to December 2008 at Taipei Medical University-Wan Fang Hospital, a 750-bed tertiary-care center and MDR-TB referral center. Hepatitis associated with prothionamide was defined as the recurrence of hepatitis after a second prothionamide treatment re-challenge. In total, 47 patients with MDR-TB enrolled in the Directly Observed Therapy, Short Course-Plus Program were identified during the study period, and 44 (93.6{\%}) were treated with prothionamide. Seven of these 44 patients (15.9{\%}) developed hepatitis after being treated with prothionamide concurrent with other anti-tuberculosis agents. Hepatitis associated with prothionamide occurred in three of these seven patients (6.8{\%}). In these three patients, hepatitis developed following treatment with prothionamide for 28 days, 39 days or 45 days. Hepatitis developed rapidly after re-challenge with prothionamide at 4 days, 4 days and 3 days, respectively. Liver function returned to the normal range after cessation of prothionamide treatment for 19 days, 27 days or 28 days. Close monitoring of liver function was necessary in MDR-TB patients who received prothionamide treatment.",
keywords = "Hepatitis, Multidrug-resistant tuberculosis, Prothionamide",
author = "Hsu, {Han Lin} and Bai, {Kuan Jen} and Chiang, {Yi Chun} and Lin, {Shian Jiun} and Yu, {Ming Chih}",
year = "2010",
month = "12",
doi = "10.1016/S0929-6646(10)60141-6",
language = "English",
volume = "109",
pages = "923--927",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier Science Publishers B.V.",
number = "12",

}

TY - JOUR

T1 - Hepatitis associated with prothionamide for treatment of multidrug-resistant tuberculosis

AU - Hsu, Han Lin

AU - Bai, Kuan Jen

AU - Chiang, Yi Chun

AU - Lin, Shian Jiun

AU - Yu, Ming Chih

PY - 2010/12

Y1 - 2010/12

N2 - Timely and intensive monitoring for, and management of, adverse effects caused by anti-tuberculosis drugs are essential components of control programs for multidrug-resistant tuberculosis (MDR-TB). This retrospective case series was conducted in northern Taiwan from January 2007 to December 2008 at Taipei Medical University-Wan Fang Hospital, a 750-bed tertiary-care center and MDR-TB referral center. Hepatitis associated with prothionamide was defined as the recurrence of hepatitis after a second prothionamide treatment re-challenge. In total, 47 patients with MDR-TB enrolled in the Directly Observed Therapy, Short Course-Plus Program were identified during the study period, and 44 (93.6%) were treated with prothionamide. Seven of these 44 patients (15.9%) developed hepatitis after being treated with prothionamide concurrent with other anti-tuberculosis agents. Hepatitis associated with prothionamide occurred in three of these seven patients (6.8%). In these three patients, hepatitis developed following treatment with prothionamide for 28 days, 39 days or 45 days. Hepatitis developed rapidly after re-challenge with prothionamide at 4 days, 4 days and 3 days, respectively. Liver function returned to the normal range after cessation of prothionamide treatment for 19 days, 27 days or 28 days. Close monitoring of liver function was necessary in MDR-TB patients who received prothionamide treatment.

AB - Timely and intensive monitoring for, and management of, adverse effects caused by anti-tuberculosis drugs are essential components of control programs for multidrug-resistant tuberculosis (MDR-TB). This retrospective case series was conducted in northern Taiwan from January 2007 to December 2008 at Taipei Medical University-Wan Fang Hospital, a 750-bed tertiary-care center and MDR-TB referral center. Hepatitis associated with prothionamide was defined as the recurrence of hepatitis after a second prothionamide treatment re-challenge. In total, 47 patients with MDR-TB enrolled in the Directly Observed Therapy, Short Course-Plus Program were identified during the study period, and 44 (93.6%) were treated with prothionamide. Seven of these 44 patients (15.9%) developed hepatitis after being treated with prothionamide concurrent with other anti-tuberculosis agents. Hepatitis associated with prothionamide occurred in three of these seven patients (6.8%). In these three patients, hepatitis developed following treatment with prothionamide for 28 days, 39 days or 45 days. Hepatitis developed rapidly after re-challenge with prothionamide at 4 days, 4 days and 3 days, respectively. Liver function returned to the normal range after cessation of prothionamide treatment for 19 days, 27 days or 28 days. Close monitoring of liver function was necessary in MDR-TB patients who received prothionamide treatment.

KW - Hepatitis

KW - Multidrug-resistant tuberculosis

KW - Prothionamide

UR - http://www.scopus.com/inward/record.url?scp=79951889240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951889240&partnerID=8YFLogxK

U2 - 10.1016/S0929-6646(10)60141-6

DO - 10.1016/S0929-6646(10)60141-6

M3 - Article

C2 - 21195892

AN - SCOPUS:79951889240

VL - 109

SP - 923

EP - 927

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

IS - 12

ER -